The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 ...

Teleflex (NYSE: TFX) announced today that it received FDA 510(k) clearance for its AC Range intra-aortic balloon pump (IABP).

WASHINGTON, DC—Updated data from the SMART trial show that supra-annular self-expanding valves yield similar clinical outcomes as balloon-expandable valves at 2 years, but with less risk of ...